Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2007

View Archived Issues

Micromet publishes two studies on its BiTE antibodies

Preclinical data on AV-101 indicate its potential for the treatment of PD

Targacept reports negative results from phase II clinical trial of TC-2696

Alpharma reports positive results from phase III trial of ALO-01 for pain relief

LifeCycle Pharma initiates phase II clinical trial of immunosuppressant LCP-Tacro

Novel therapeutic agents for neurological disorders reported in recent patents

Novel therapeutic agents for allergic and respiratory disorders disclosed in recent patents

4SC reports positive initial results from phase IIa clinical study of SC-12267 for RA

Recent Vitae patent discloses novel antihypertensive agents

OncoVista licenses OSI-7904L from OSI Pharmaceuticals

Arana Therapeutics provides an update on the clinical development plans for ART-621

Elan presents third quarter 2007 results

In vivo antimetastatic activity of novel irreversible uPA inhibitors

Mirodenafil significantly improves erectile dysfunction in double-blind study

Treatment effects and cardiovascular safety of dapoxetine assessed in phase III study

Rasagiline may slow deterioration of amyotrophic lateral sclerosis

Nippon Kayaku initiates phase II study of NK-105

Seikagaku initiates phase II study of SI-6603 for lumbar disc herniation

BioMarin enters research and option agreement with IGAN for IgA proteases

Eisai and BioArctic sign licensing agreement for BAN-2401 for Alzheimer's disease

NeuroSearch initiates phase I clinical study of NSD-644 for the treatment of pain

Bayer Schering Pharma takes next step towards important oral contraceptive milestone

Betaferon is only drug to delay disability in patients treated after first MS attack

Intercell's MAA for Japanese encephalitis vaccine is submitted to EMEA

E.U. approves Vectibix for the treatment of metastatic colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...